Genome-wide miRNA profiling in plasma of pregnant women with down syndrome fetuses
- PMID: 32472298
- PMCID: PMC7295716
- DOI: 10.1007/s11033-020-05545-w
Genome-wide miRNA profiling in plasma of pregnant women with down syndrome fetuses
Abstract
Down syndrome (DS) is one of the most common causes of intellectual disability and new approaches allowing its rapid and effective prenatal detection are being explored. In this study, we investigated the diagnostic potential of plasma microRNAs (miRNAs). This study builds upon our previous study in DS placentas, where seven miRNAs were found to be significantly up-regulated. A total of 70 first-trimester plasma samples from pregnant women were included in the present study (35 samples with DS fetuses; 35 with euploid fetuses). Genome-wide miRNA profiling was performed in the pilot study using Affymetrix GeneChip™ miRNA 4.1 Array Strips (18 samples). Selected miRNAs were then analysed in the validation study using quantitative reverse transcription PCR (RT-qPCR; 52 samples). Based on the current pilot study results (12 miRNAs), our previous research on chorionic villi samples (7 miRNAs) and the literature (4 miRNAs), a group of 23 miRNAs was selected for the validation study. Although the results of the pilot study were promising, the validation study using the more sensitive RT-qPCR technique and a larger group of samples revealed no significant differences in miRNA profiles between the compared groups. Our results suggest that testing of the first-trimester plasma miRNAs is probably not suitable for non-invasive prenatal testing (NIPT). Different results could be theoretically achieved at later gestational ages; however, such a result probably would have limited use in clinical practice.
Keywords: Down syndrome; Fetal aneuploidy; Liquid biopsy; NIPT; Trisomy 21; miRNA.
Conflict of interest statement
The authors declare that they have no conflict of interests.
Figures


Similar articles
-
Genome-wide microRNA expression profiling in placentas of fetuses with Down syndrome.Placenta. 2015 Mar;36(3):322-8. doi: 10.1016/j.placenta.2014.12.020. Epub 2015 Jan 5. Placenta. 2015. PMID: 25595853
-
MicroRNAs as potential biomarkers for noninvasive detection of fetal trisomy 21.J Assist Reprod Genet. 2015 May;32(5):827-37. doi: 10.1007/s10815-015-0429-y. Epub 2015 Mar 8. J Assist Reprod Genet. 2015. PMID: 25749789 Free PMC article.
-
The screening of diagnostic biomarker microRNA in first-trimester maternal plasma for Down syndrome: A study protocol.Medicine (Baltimore). 2022 Jan 21;101(3):e28495. doi: 10.1097/MD.0000000000028495. Medicine (Baltimore). 2022. PMID: 35060501 Free PMC article.
-
From Down syndrome screening to noninvasive prenatal testing: 20 years' experience in Taiwan.Taiwan J Obstet Gynecol. 2013 Dec;52(4):470-4. doi: 10.1016/j.tjog.2013.10.003. Taiwan J Obstet Gynecol. 2013. PMID: 24411028 Review.
-
Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center.Ultrasound Obstet Gynecol. 2014 Mar;43(3):254-64. doi: 10.1002/uog.13277. Epub 2014 Feb 10. Ultrasound Obstet Gynecol. 2014. PMID: 24339153 Review.
Cited by
-
[Whole-transcriptome sequencing analysis of placental differential miRNA expression profile in Down syndrome].Nan Fang Yi Ke Da Xue Xue Bao. 2022 Mar 20;42(3):418-424. doi: 10.12122/j.issn.1673-4254.2022.03.15. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 35426807 Free PMC article. Chinese.
-
Are there foetal extracellular vesicles in maternal blood? Prospects for diagnostic biomarker discovery.J Mol Med (Berl). 2023 Feb;101(1-2):65-81. doi: 10.1007/s00109-022-02278-0. Epub 2022 Dec 20. J Mol Med (Berl). 2023. PMID: 36538060 Free PMC article. Review.
-
Novel method of real-time PCR-based screening for common fetal trisomies.BMC Med Genomics. 2021 Jul 30;14(1):195. doi: 10.1186/s12920-021-01039-1. BMC Med Genomics. 2021. PMID: 34330281 Free PMC article.
-
Detection of Embryonic Trisomy 21 in the First Trimester Using Maternal Plasma Cell-Free RNA.Diagnostics (Basel). 2022 Jun 7;12(6):1410. doi: 10.3390/diagnostics12061410. Diagnostics (Basel). 2022. PMID: 35741220 Free PMC article.
-
Assessment of NanoString technology as a tool for profiling circulating miRNA in maternal blood during pregnancy.Extracell Vesicles Circ Nucl Acids. 2024 Sep 5;5(3):471-496. doi: 10.20517/evcna.2024.38. eCollection 2024. Extracell Vesicles Circ Nucl Acids. 2024. PMID: 39697629 Free PMC article.
References
-
- Organization WH. https://www.who.int/genomics/public/geneticdiseases/en/index1.html. Accessed 25 Jan 2018
-
- Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, Bianchi DW. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in down syndrome fetuses. Proc Natl Acad Sci USA. 2009;106(23):9425–9429. doi: 10.1073/pnas.0903909106. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical